NEW YORK (TheStreet) -- CHANGE IN RATINGS
downgraded at Barclays to Equal Weight from Overweight due to uncertainty on financial reform impacts. Price target dropped to $36 from $39.
upgraded at Baird from Neutral to Outperform. $35 price target. Valuation call, given a more upbeat outlook for the industry.
upgraded at Morgan Stanley from Underweight to Equal-weight. $39 price target. Company deserves a premium multiple.
upgraded at UBS from Neutral to Buy. $15.50 price target. Estimates cut because of market share losses, but the company can still benefit from the PC refresh cycle.
Entertainment Properties Trust
upgraded at Citi to Buy from Hold on dividend growth and reduced risk profile. Maintain $46 price target.
upgraded at Citi to Hold from Sell. Valuation call. Maintain $10 price target.
initiated at Credit Suisse with a Neutral rating and $27 price target. FRX has both one of the largest patent cliff and pipeline replacement potential.
downgraded at Morgan Stanley to Equal-weight. $65 price target. Company is hurt by uncertainty in the Gulf and has limited near-term drilling prospects.
initiated at Piper Jaffray. Initiated with a Neutral rating and $17 price target. Introduces 2010 EPS estimates of $0.62.
initiated at Credit Suisse with a Neutral rating and $14 price target. Linaclotide is a potential best in class prescription drug.
initiated at Piper Jaffray. Initiated with an Overweight rating and $42 price target. Introduces 2010 EPS estimates of $1.52.
upgraded at Citi to Buy from Hold on a tactical trading opportunity. Maintain $13 price target.
initiated at Piper Jaffray. Initiated with a Neutral rating and $23 price target. Introduces 2010 EPS estimates of $0.76.
resumed and upgraded at Goldman with a Neutral rating and $34 price target. Stock is already largely pricing in a cyclical earnings recovery.
Smith & Wesson
upgraded at Merriman from Neutral to Buy. Company had a strong quarter and should benefit from an improving backlog.
downgraded at Baird from Outperform to Neutral. $55 price target. Valuation call, given the new sector outlook.
initiated at Piper Jaffray. Initiated with an Overweight rating and $28 price target. Introduces 2010 EPS estimates of $1.07.
upgraded at Citi to Buy from Hold. Attractive valuation, well positioned balance sheet, and improving portfolio conditions. Maintain $24 price target.
STOCK COMMENTS / EPS CHANGES
target lowered at Goldman to $50. Gulf spill will continue to weigh on the stock. Neutral rating.
estimates changed at Barclays. APOL 2010 EPS estimate increased to $5.32, 2011 lowered to $5.52. An accelerated orientation program rollout will limit near-term profit growth. Maintain Overweight rating and $68 price target.
added to Top Picks list at Citigroup. $28 price target. Positive meeting with management suggests that business is on track and that the company will continue to pay down debt.
price target lower at BofA/Merrill. CADX price target trimmed to $8 from $11 on more conservative Ofirmev sales. Maintain Neutral rating.
target increased at UBS to $37. Company should achieve near-term goals, given non-soup growth and cost controls. Neutral rating.
price target trimmed at Barclays to $37 from $40 as home improvement spending remains volatile. Maintain Overweight rating.
price target cut at BofA/Merrill to $36 from $47. M&A backlog continues to rise, but the pace of closings will be slower in 2H10. Reiterate Buy.
price target cut at BofA/Merrill to $29 from $32 to reflect the disposition of access lines to Frontier. Maintain Neutral rating.
This article was written by a staff member of TheStreet.com.